2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2830

Synovial Fluid T Cells of Patients with Reactive Arthritis and Undifferentiated Spondyloarthropathy Respond to Salmonella Typhimurium Outer Membrane Protein a and Induces IL17 and IL23 Production By Synovial Fluid Mononuclear Cells
Abstract Number: 3098

Synovial Lymphocytic Aggregates Associate with Highly Active RA and Predict Erosive Disease at 12 Months: Results from the Pathobiology of Early Arthritis Cohort
Abstract Number: 1361

Synovial Macrophages Promote TGF-β Signaling but Protect Against Influx of S100A8/S100A9-Producing Cells after Intra-Articular Injections of Oxidized Low-Density Lipoproteins
Abstract Number: 1161

Synovial Th9 Cells Prolong Neutrophil Survival and Functionally Enhance the Infiltrating T Cells in Rheumatoid Arthritis
Abstract Number: 1141

Synovial Ultrasound Power Doppler Enhancement Reflects Multiple Cytokine Expression in Synovial Tissue, Distinguishing Distinct High Macrophage-Associated and Low Inflammation Profiles
Abstract Number: 1035

Synovium-Derived microRNAs Inhibit Bone Formation in Rheumatoid Arthritis
Abstract Number: 1240

Systematic Protein-Protein Interaction and Pathway Analyses in the Idiopathic Inflammatory Myopathies
Abstract Number: 1676

Systematic Review and Network Meta-Analysis of Combination Treatments in Disease Modifying Anti-Rheumatic Drug Experienced Patients with Severe Rheumatoid Arthritis: Analysis of American College of Rheumatology Criteria Scores 20, 50, and 70: An Update
Abstract Number: 3250

Systemic Inflammation and Pain Sensitization in Knee Osteoarthritis: The Multicenter Osteoarthritis Study
Abstract Number: 2803

Systemic Interferon Type I and Type II Signatures Present in Distinct Subsets of Primary Sjögren’s Syndrome: En Route Towards More Selective Targeting
Abstract Number: 1842

Systemic Lupus Erythematosus and Chikungunya Fever: Interactions during the 2014 Outbreak in Martinique
Abstract Number: 717

Systemic Lupus Erythematosus and the Evaluation of Poor Sleep: The Sleeps Pilot Study
Abstract Number: 1835

Systemic Lupus Erythematosus Does Not Increase Risk of Adverse Events in the First 6 Months after Total Knee Replacement
Abstract Number: 1855

Systemic Lupus Erythematosus Exosomes Contain Distinct RNA Transcripts That Differentiate Disease Activity and Modulate Cellular Function
Abstract Number: 3159

Systemic Lupus Erythematosus Is a Risk Factor for Young Stroke: A Population-Based Cohort Study

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].